Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: 249443 who wrote (77)	7/8/2002 12:00:57 PM
From: AurumRabosa	Respond to of 684

"Genetics and genomics will play a major role in the future of the healthcare industry," said Alen Roses, head of genetics research at GlaxoSmithKline. Over the next two to five years, the biggest use of genetic information will likely be to create genetic profiles to establish who is most likely to benefit from existing drugs and who is most liable to suffer a potentially serious side effect, he said. "Creating safer products is becoming even more necessary if they are to compete in this highly regulated market," Roses said. So can this be construed as a plug for the technology VGNX is developing?

To: 249443 who wrote (77)	7/8/2002 12:04:58 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 684

>> A company with a significant burn rate will simply run out of cash << This story gets popular, once every five years or so. The sector is 25 years old, and it simply happens on rare occasion. Enabling patents and preclinical research have value. On occasion (e.g., '93-'94, summer '98, and, IMO, the present), they are discounted. >> 2) the lack of biotech product advancement << Are you talking recent, highly publicized product failures and/or problems with FDA, or are you wading in dogma? A wide variety of first-in-class medicines has been approved and marketed. Others are, of course, in advanced clinical testing. Biotech investors, given time and expertise, generally do quite well. If you have no scientific expertise and don't follow anyone with such, then you shouldn't invest in the sector. Most companies will fail to thrive. The first of the "genomics derived" products are already approved, and many more are advancing in clinical trials. Toni Clarke's article is, IMO, filled with dogma and fluff crap.